MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

BioCryst Pharmaceuticals Company Profile (NASDAQ:BCRX)

Consensus Ratings for BioCryst Pharmaceuticals (NASDAQ:BCRX) (?)
Ratings Breakdown: 1 Sell Rating(s), 5 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Hold (Score: 2.36)
Consensus Price Target: $9.70 (186.98% upside)

Analysts' Ratings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Show:
DateFirmActionRatingPrice TargetActions
5/9/2016HC WainwrightReiterated RatingBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016FBR & Co.Reiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2016Noble FinancialReiterated RatingBuy$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2016Jefferies GroupDowngradeBuy -> Hold$14.00 -> $2.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2016Rodman & RenshawLower Price TargetBuy$24.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$16.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/8/2016Needham & Company LLCDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/8/2016Piper JaffrayDowngradeOverweight -> Neutral$15.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/13/2016JMP SecuritiesLower Price Target$17.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/11/2015Bank of AmericaDowngradeNeutral -> Underperform$12.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/10/2015OppenheimerReiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/10/2015MLV & Co.Reiterated RatingBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/23/2014Wells FargoUpgradeMarket Perform -> Outperform$19.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/29/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha